In vivo study of light-driven naproxen release from gated mesoporous silica drug delivery system

Almáši, Miroslav; Matiašová, Anna Alexovič; Šuleková, Monika; Beňová, Eva; Ševc, Juraj; Váhovská, Lucia; Lisnichuk, Maksym; Girman, Vladimír; Zeleňáková, A.; Hudák, Alexander; Zeleňák, Vladimı́r

doi:10.1038/s41598-021-99678-y

Cited by 30 publications

(18 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HPMC K 4 M also exhibits a high swelling capacity, which can further aid in providing sustained drug delivery vehicles [43]. Such vehicles help to effectively transfer the target molecule to the site of action [44]. PVP is widely used to increase the residence time of many topical ophthalmic products by way of its viscosity-enhancing and mucoadhesive properties.…”

Section: Addition Of Mucoadhesive Agents To the Mox-ne Formulationmentioning

confidence: 99%

Design of Topical Moxifloxacin Mucoadhesive Nanoemulsion for the Management of Ocular Bacterial Infections

et al. 2022

View full text Add to dashboard Cite

Ocular bacterial infections can lead to serious visual disability without proper treatment. Moxifloxacin (MOX) has been approved by the US Food and Drug Administration as a monotherapy for ocular bacterial infections and is available commercially as an ophthalmic solution (0.5% w/v). However, precorneal retention, drainage, and low bioavailability remain the foremost challenges associated with current commercial eyedrops. With this study, we aimed to design a MOX-loaded nanoemulsion (NE; MOX-NE) with mucoadhesive agents (MOX-NEM) to sustain MOX release, as well as to overcome the potential drawbacks of the current commercial ophthalmic formulation. MOX-NE and MOX-NEM formulations were prepared by hot homogenization coupled with probe sonication technique and subsequently characterized. The lead formulations were further evaluated for in vitro release, ex vivo transcorneal permeation, sterilization, and antimicrobial efficacy studies. Commercial MOX ophthalmic solution was used as a control. The lead formulations showed the desired physicochemical properties and viscosity. All lead formulations showed sustained release profiles a period of more than 12 h. Filtered and autoclaved lead formulations were stable for one month (the last time point tested) under refrigeration and at room temperature. Ex vivo transcorneal permeation studies revealed a 2.1-fold improvement in MOX permeation of the lead MOX-NE formulation compared with Vigamox® eyedrops. However, MOX-NEM formulations showed similar flux and permeability coefficients to those of Vigamox® eyedrops. The lead formulations showed similar in vitro antibacterial activity as the commercial eyedrops and crude drug solution. Therefore, MOX-NE and MOX-NEM formulations could serve as effective delivery vehicles for MOX and could improve treatment outcomes in different ocular bacterial infections.

show abstract

Section: Addition Of Mucoadhesive Agents To the Mox-ne Formulationmentioning

confidence: 99%

Design of Topical Moxifloxacin Mucoadhesive Nanoemulsion for the Management of Ocular Bacterial Infections

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In the past 20 years, the combination of nanotechnology and pharmaceutics has brought possibility for the realization of oral administration of macromolecular drugs [ 36 , 37 , 38 ], and it is also a promising research direction of oral insulin [ 39 , 40 ]. In this review, we summarize the physiological absorption barriers of oral insulin and discuss the nano-drug delivery systems constructed from different materials ( Figure 1 ).…”

Section: Introductionmentioning

confidence: 99%

Versatile Oral Insulin Delivery Nanosystems: From Materials to Nanostructures

Wang

Ren

et al. 2022

IJMS

View full text Add to dashboard Cite

Diabetes is a chronic metabolic disease characterized by lack of insulin in the body leading to failure of blood glucose regulation. Diabetes patients usually need frequent insulin injections to maintain normal blood glucose levels, which is a painful administration manner. Long-term drug injection brings great physical and psychological burden to diabetic patients. In order to improve the adaptability of patients to use insulin and reduce the pain caused by injection, the development of oral insulin formulations is currently a hot and difficult topic in the field of medicine and pharmacy. Thus, oral insulin delivery is a promising and convenient administration method to relieve the patients. However, insulin as a peptide drug is prone to be degraded by digestive enzymes. In addition, insulin has strong hydrophilicity and large molecular weight and extremely low oral bioavailability. To solve these problems in clinical practice, the oral insulin delivery nanosystems were designed and constructed by rational combination of various nanomaterials and nanotechnology. Such oral nanosystems have the advantages of strong adaptability, small size, convenient processing, long-lasting pharmaceutical activity, and drug controlled-release, so it can effectively improve the oral bioavailability and efficacy of insulin. This review summarizes the basic principles and recent progress in oral delivery nanosystems for insulin, including physiological absorption barrier of oral insulin and the development of materials to nanostructures for oral insulin delivery nanosystems.

show abstract

“…However, many hurdles can hamper drug targeting to the brain, such as the blood–brain barrier (BBB), which blocks most neurological drugs administered either orally or via the invasive parental route, leading to side effects, as the drugs can affect non-targeted organs [ 5 , 6 ]. There is a high demand for targeted and effective drug delivery to the site of action in the organism [ 7 ]. Among them, the development of non-invasive drug delivery to the brain for treatment of chronic central nervous system disorders is challenging.…”

Section: Introductionmentioning

confidence: 99%

A Brain-Targeted Approach to Ameliorate Memory Disorders in a Sporadic Alzheimer’s Disease Mouse Model via Intranasal Luteolin-Loaded Nanobilosomes

et al. 2022

View full text Add to dashboard Cite

Impaired memory and cognitive function are the main features of Alzheimer’s disease (AD). Unfortunately, currently available treatments cannot cure or delay AD progression. Moreover, the blood–brain barrier hampers effective delivery of treatment to the brain. Therefore, we aimed to evaluate the impact of intranasally delivered luteolin on AD using bile-salt-based nano-vesicles (bilosomes). Different bilosomes were prepared using 23-factorial design. The variables were defined by the concentration of surfactant, the molar ratio of cholesterol:phospholipid, and the concentration of bile salt. Results demonstrated optimized luteolin-loaded bilosomes with particle size (153.2 ± 0.98 nm), zeta potential (−42.8 ± 0.24 mV), entrapment efficiency% (70.4 ± 0.77%), and % drug released after 8 h (80.0 ± 1.10%). In vivo experiments were conducted on an AD mouse model via intracerebroventricular injection of 3 mg/kg streptozotocin. We conducted behavioral, biochemical marker, histological, and immune histochemistry assays after administering a luteolin suspension or luteolin bilosomes (50 mg/kg) intranasally for 21 consecutive days. Luteolin bilosomes improved short-term and long-term spatial memory. They also exhibited antioxidant properties and reduced levels of proinflammatory mediators. They also suppressed both amyloid β aggregation and hyperphosphorylated Tau protein levels in the hippocampus. In conclusion, luteolin bilosomes are an effective, safe, and non-invasive approach with superior cognitive function capabilities compared to luteolin suspension.

show abstract

In vivo study of light-driven naproxen release from gated mesoporous silica drug delivery system

Cited by 30 publications

References 42 publications

Design of Topical Moxifloxacin Mucoadhesive Nanoemulsion for the Management of Ocular Bacterial Infections

Design of Topical Moxifloxacin Mucoadhesive Nanoemulsion for the Management of Ocular Bacterial Infections

Versatile Oral Insulin Delivery Nanosystems: From Materials to Nanostructures

A Brain-Targeted Approach to Ameliorate Memory Disorders in a Sporadic Alzheimer’s Disease Mouse Model via Intranasal Luteolin-Loaded Nanobilosomes

Contact Info

Product

Resources

About